BlackRock Science and Technology Trust II (BSTZ) is a closed-end fund managed by BlackRock, specializing in high-growth investment opportunities within the science and technology sectors. The fund strategically targets innovative companies at the cutting edge of technological advancements and scientific research, aiming to harness their substantial growth potential. With BlackRock's robust industry expertise, BSTZ endeavors to deliver attractive total returns to institutional investors through a balanced strategy that encompasses both capital appreciation and income generation. This investment vehicle not only offers opportunities for portfolio diversification but also positions investors to benefit from enduring trends in technology and healthcare innovation.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | — |
| Price-to-Book | 1.18 |
| Price-to-Sales (TTM) | 6.39 |
| EV/Revenue | 6.39 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $68.74M |
| Float | 0 |
| % Insiders | 0.01% |
| % Institutions | 30.95% |
Volatility is currently expanding
BlackRock Science and Technology Term Trust offers pre-IPO exposure to high-profile tech firms like Anthropic. BSTZ focuses on total return and income, targeting long-term capital appreciation in U.S. and non-U.S. science and technology equities. As a closed-end fund, BSTZ trades at a discount or premium to NAV (currently a discount), thus creating potential for additional returns if the discount narrows.
The BlackRock Science and Technology Term Trust (NYSE:BSTZ) is an unusual tech vehicle: a closed-end fund with a 2031 liquidation date, an expense ratio near 1.4%, and over 30% of its portfolio invested in private, pre-IPO companies.
BlackRock Science & Technology Term Trust (NYSE:BSTZ) is a closed-end fund with a fixed expiration date, a covered call overlay, and more than 30% of its portfolio locked in private, pre-IPO companies that most investors cannot access through a brokerage account.
BlackRock Science & Technology Term Trust (NYSE:BSTZ) is a closed-end fund (CEF) that combines a venture-stage technology portfolio with a covered call writing strategy to deliver monthly income.
BSTZ has dramatically shifted its portfolio, now heavily concentrated in private, illiquid technology and AI investments. BSTZ's private assets, including Anthropic at 15% of holdings, now comprise nearly half the portfolio, heightening liquidity and valuation risks. Distribution and management changes, along with increased private exposure, have altered BSTZ's risk profile and diverged from its original mandate.
BlackRock Science and Technology Term Trust (NYSE:BSTZ) has gained 57.79% over the past year, with shares recently touching $23.92.
There are three stories moving markets right now:
